Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07810777
PHASE2

PRA-216 Atopic Dermatitis Safety and Efficacy Study

Sponsor: Prana Therapies Inc

View on ClinicalTrials.gov

Summary

This study will evaluate the safety, tolerability, pharmacokinetics and immunogenicity of PRA-216 compared to placebo in patients with moderate to severe Atopic Dermatitis (AD)

Official title: A Phase 2 Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Evaluate the Safety and Efficacy of PRA-216 in Participants With Moderate to Severe Atopic Dermatitis

Key Details

Gender

All

Age Range

18 Years - 70 Years

Study Type

INTERVENTIONAL

Enrollment

39

Start Date

2026-09-01

Completion Date

2027-10-01

Last Updated

2026-09-09

Healthy Volunteers

No

Interventions

DRUG

Active PRA-216

biologic

DRUG

Placebo

matching placebo for PRA-216

Locations (8)

Emeritus Sydney

Botany, New South Wales, Australia

Cornerstone Centre for Clinical Research

Coorparoo, Queensland, Australia

Emeritus Melbourne

Camberwell, Victoria, Australia

Momentum Sunshine

Melbourne, Victoria, Australia

Optimal Clinical Trials (North)

Auckland, New Zealand

Aotearoa Clinical Trials

Auckland, New Zealand

Momentum Christchurch

Christchurch, New Zealand

Clinical Trials New Zealand

Hamilton, New Zealand